RT Journal Article
SR Electronic
T1 First Reported Use of the Faxitron LOCalizer™ Radiofrequency Identification (RFID) System in Europe – A Feasibility Trial, Surgical Guide and Review for Non-palpable Breast Lesions
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1559
OP 1564
DO 10.21873/invivo.11637
VO 33
IS 5
A1 WOLFRAM MALTER
A1 JOHANNES HOLTSCHMIDT
A1 FABINSHY THANGARAJAH
A1 PETER MALLMANN
A1 BARBARA KRUG
A1 MATHIAS WARM
A1 CHRISTIAN EICHLER
YR 2019
UL http://iv.iiarjournals.org/content/33/5/1559.abstract
AB Background/Aim: The problem of adequately marking any given lesion within a breast surgical site is commonly solved by introducing a titanium clip. However, clip dislocation and/or stereotactic hook-wire dislocation are common problems. An ideal solution would be a clip that can be easily found without the use of stereotactic intervention. This work reviews the available data on radiofrequency identification devices (RFID) in breast surgery, reports initial experience data in Europe and discusses surgical pitfalls, advantages and disadvantages. Patients and Methods: This study represents a single center, consecutively recruited, initiation trial with subsequent surgeon questionnaire for the first institution in Europe to report Faxitron LOCalizer™ chip data. Four patients with non-palpable tumors were marked with the system and were correlated via mammography, pre- and intra-operative ultrasound and pathology. Data were then compared to available literature and a literature review was added. Results: The four patients marked with this RFID system, displayed a 100% success location rate at a 0% complication rate. Surgeons evaluated the new system as being safe to use and only slightly more difficult to place compared to a standard clip. A significant improvement in ultrasound localization and intraoperative localization was also reported for the LOCalizer™ system when compared to a standard titanium clip. Conclusion: This trial added a small number of consecutively recruited patients to an existing number of available data, resulting in a total of 121 evaluated and reviewed Faxitron LOCalizer™ marked non-palpable in-breast lesions worldwide.